Ucb

Ucb Debt

The Debt of Ucb (UCB.BR) as of Nov 19, 2026 is 2.25 B EUR. In the previous year, Debt was 3.03 B EUR — a change of -25.81% (lower).

Debt

2.25 BEUR

YoY

-25.81%

Last updated:

In 2025, Ucb's total debt was 2.25 B EUR, a -25.81% change from the 3.03 B EUR total debt recorded in the previous year.

The Ucb Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
1.50 B EUR
Jan 1, 2019
1.28 B EUR
Jan 1, 2020
2.75 B EUR
Jan 1, 2021
2.12 B EUR
Jan 1, 2022
2.90 B EUR
Jan 1, 2023
3.04 B EUR
Jan 1, 2024
3.03 B EUR
Jan 1, 2025
2.25 B EUR
The Ucb Debt history
YEARDebtYoY
2.25 BEUR-25.81%
3.03 BEUR-0.39%
3.04 BEUR+4.76%
2.90 BEUR+36.60%
2.12 BEUR-22.72%
2.75 BEUR+114.44%
1.28 BEUR-14.54%
1.50 BEUR-4.70%
1.57 BEUR-1.75%
1.60 BEUR-36.04%
2.50 BEUR+18.07%
2.12 BEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ucb Stock analysis

What does Ucb do? The company UCB SA is a Belgian pharmaceutical company that was founded in 1928 and is now active worldwide. The business model of UCB SA is based on the discovery and development of medications for severe diseases. The core competencies of the company are in neurology, immunology, and cardiology. In the history of UCB SA, there are several milestones. In 1961, UCB SA succeeded in synthesizing antihistamines, which marked the beginning of the development of medications for allergic diseases. In the 1990s, UCB SA began to focus on the development of medications for the treatment of epilepsy and Parkinson's disease. In the 2000s, UCB SA acquired several companies, expanding its portfolio of medications and its geographic reach. The company operates three different divisions: pharmaceuticals, biopharmaceuticals, and specialty chemicals. In the pharmaceuticals division, UCB SA develops and distributes medications for the treatment of epilepsy, Parkinson's disease, and autoimmune diseases such as rheumatoid arthritis and lupus. UCB SA's biopharmaceutical division focuses on researching antibodies for the treatment of various diseases such as cancer and multiple sclerosis. In the specialty chemicals division, UCB SA produces chemical products such as solvents and paints. The company offers a wide range of products tailored to the needs of patients with various diseases. One example of a well-known product from UCB SA is Keppra, a medication for the treatment of epilepsy. Keppra is one of the most prescribed medications for epilepsy and has helped improve the lives of millions of patients. Another example is Cimzia, a medication for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Cimzia belongs to a new generation of medications that aim to selectively influence the immune system and thus inhibit inflammation. UCB SA places great value on innovation and constantly researches new medications and therapies. The company has a strong research and development team with over 3,000 employees and invests approximately 25% of its revenue annually in the research and development of new medications. Overall, UCB SA is an innovative and successful pharmaceutical company with a broad portfolio of medications and a strong commitment to the quality of the products developed. The company is dedicated to improving the lives of patients with severe diseases and remains a key player in the global pharmaceutical industry in the long term. Ucb is one of the most popular companies on Eulerpool.

Debt Details

Understanding Ucb's Debt Structure

Ucb's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Ucb's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Ucb’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Ucb’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Ucb stock

Debt of Ucb is 2.25 B EUR in 2025.

Debt of Ucb changed from 3.03 B EUR to 2.25 B EUR, representing a -25.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Ucb since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Ucb historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ucb

All Key Metrics — Ucb